Genetic Variation in <i>CYP2D6</i>, <i>UGT1A4</i>, <i>SLC6A2</i> and <i>SLCO1B1</i> Alters the Pharmacokinetics and Safety of Mirabegron

Mirabegron is a drug used in overactive bladder (OAB) treatment. Genetic variation in pharmacogenes might alter its pharmacokinetics, affecting its efficacy and safety. This research aimed to analyze the impact of genetic variation on mirabegron pharmacokinetics and safety. Volunteers from three bio...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Paula Soria-Chacartegui, Patricia Cendoya-Ramiro, Eva González-Iglesias, Samuel Martín-Vílchez, Andrea Rodríguez-Lopez, Gina Mejía-Abril, Manuel Román, Sergio Luquero-Bueno, Dolores Ochoa, Francisco Abad-Santos
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2024-08-01
coleção:	Pharmaceutics
Assuntos:	mirabegron pharmacogenetics <i>CYP2D6</i> overactive bladder pharmacokinetics
Acesso em linha:	https://www.mdpi.com/1999-4923/16/8/1077
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!